Immutep Limited (ASX:IMM) Announces Positive Phase I Results for IMP761
Immutep (ASX:IMM) reports positive Phase I results for IMP761, showing significant T cell suppression and favourable safety profile.
Category: Healthcare
Neurizon Therapeutics Limited (ASX:NUZ) Reports New Preclinical Data Supporting ALS Treatment
Neurizon Therapeutics (ASX:NUZ) announces positive preclinical results for NUZ-001, highlighting its potential as a transformative ALS therapy.
Race Oncology Ltd (ASX:RAC) Initiates Phase 1 RC220 + Doxorubicin Trial
Race Oncology (ASX:RAC) safely doses first patient in Phase 1 RC220 + Doxorubicin trial, advancing solid tumour treatments.
Mayne Pharma Group Limited (ASX:MYX) Approves Acquisition by Cosette Pharmaceuticals
Mayne Pharma Group Limited (ASX:MYX) shareholders approve Cosette Pharmaceuticals’ acquisition with 99.06% voting in favor.
4DMedical Limited (ASX:4DX) Expands Contract with Stanford University
4DMedical Limited (ASX:4DX) expands its contract with Stanford University, including new imaging technologies ahead of FDA clearance.
Recce Pharmaceuticals (ASX:RCE) Secures A$30m Non-Dilutive Financing
Recce Pharmaceuticals (ASX:RCE) secures a A$30m debt facility with Avenue Capital Group to support Phase 3 trials.
EVE Health Group (ASX:EVE) Completes Nextract Acquisition
EVE Health Group (ASX:EVE) completes acquisition of Nextract, bolstering its position in the healthcare market.
AnteoTech Ltd (ASX:ADO) Reports 130% Sales Growth in Life Sciences Unit
AnteoTech Ltd (ASX:ADO) reports a 130% sales increase in its Life Sciences unit and secures a significant order from the Serum Institute of India.
dorsaVi Ltd (ASX:DVL) Secures Exclusive Worldwide Licence for Advanced RRAM Technology
dorsaVi Ltd (ASX:DVL) secures an exclusive worldwide licence for advanced RRAM technology, enhancing its wearable sensors and expanding market opportunities.
Bioxyne Limited (ASX:BXN) Upgrades FY2025 Revenue Guidance
Bioxyne Limited (ASX:BXN) upgrades its FY2025 revenue guidance to $28m, driven by significant growth in Australian operations and European expansion.